Soluble guanylate cyclase

Assets acting on this target.

Class
Soluble guanylate cyclase stimulator

Soluble guanylate cyclase (sGC) is an enzyme found in smooth muscle and other tissues that converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), a molecule that relaxes blood vessel walls and reduces the buildup of scar-like tissue. Under normal conditions, sGC is activated when nitric oxide (NO), a gas produced by the lining of blood vessels, binds to it. In many cardiovascular and pulmonary diseases, NO production or signaling is impaired, leaving blood vessels stiffer and narrower than they should be. sGC stimulators are small molecules that bind the enzyme directly, making it more responsive to whatever NO is still present and also activating it somewhat independently of NO. The result is increased cGMP production, promoting vasodilation, lowering blood pressure in affected vessels, and countering tissue remodeling. This mechanism is broadly relevant in conditions marked by insufficient NO signaling, including pulmonary hypertension, where blood pressure in the lung arteries is abnormally elevated, and heart failure, where reduced NO bioavailability contributes to vascular stiffness and poor cardiac performance. By restoring downstream signaling rather than trying to boost NO supply itself, these agents offer a way to support vascular relaxation even when the upstream signal is deficient.

By indication

Related mechanisms

Soluble guanylate cyclase drugs compared

6 drugs, stage by indication
6 drugs acting on Soluble guanylate cyclase: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
RiociguatAdempasBayer, Merck & Co.small moleculeApprovedApproved in Pulmonary Arterial Hypertension
VericiguatVerquvoBayer, Merck & Co.small moleculeApprovedApproved in Heart Failure
MosliciguatBayer, Pulmovant, Roivant Sciences Ltd.small moleculePhase 3Phase 3 in Pulmonary Hypertension Associated with Interstitial Lung Disease
NurandociguatBayersmall moleculePhase 2Phase 2 in Chronic Kidney Disease; Phase 1 in Hypertension
PraliciguatAkebia Therapeuticssmall moleculePhase 2Phase 2 in Chronic Kidney Disease; Phase 2 in Focal Segmental Glomerulosclerosis
SK-08Consun Pharmaceutical Groupsmall moleculePhase 1Phase 1 in Chronic Kidney Disease

← all mechanisms